You are here

  • Home
  • Archive
  • Volume 64, Issue 6
  • Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma

Article Text

Article menu
Download PDFPDF
Concise report
Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjögren’s syndrome and associated MALT lymphoma
  1. J Pijpe1,
  2. G W van Imhoff2,
  3. A Vissink1,
  4. J E van der Wal3,
  5. P M Kluin3,
  6. F K L Spijkervet1,
  7. C G M Kallenberg4,
  8. H Bootsma5
  1. 1Department of Oral and Maxillofacial Surgery, University Hospital Groningen, Groningen, The Netherlands
  2. 2Department of Haematology, University Hospital Groningen, Groningen, The Netherlands
  3. 3Department of Pathology and Laboratory Medicine, University Hospital Groningen, Groningen, The Netherlands
  4. 4Department of Clinical Immunology, University Hospital Groningen, Groningen, The Netherlands
  5. 5Department of Rheumatology, University Hospital Groningen, Groningen, The Netherlands
  1. Correspondence to:
    Dr J Pijpe
    Department of Oral and Maxillofacial Surgery, University Hospital Groningen, PO Box 30.001, 9700 RB Groningen, The Netherlands; j.pijpekchir.azg.nl

Abstract

Objectives: To report the successful use of rituximab on salivary gland immunohistology and function in a patient with Sjögren’s syndrome (SS) and associated MALT lymphoma.

Case report: The patient was a 42 year old woman with primary SS and associated MALT lymphoma located in the parotid gland and the hard palate. Four infusions of rituximab (375 mg/m2) weekly resulted in complete remission of the lymphoma. An incision biopsy of the parotid gland before and after treatment showed improvement of the (immuno)histopathological characteristics of SS, with possible regeneration of salivary gland tissue. Furthermore, salivary analysis showed decreased inflammatory characteristics and increased stimulated salivary flow.

Discussion: Rituximab is a promising agent in the treatment of SS associated MALT lymphoma. In addition to the effect on MALT lymphoma, B cell depletion by rituximab may also attenuate the activity of SS. This case report is the first to describe the effect of rituximab on histological and sialometric/chemical characteristics of SS. The efficacy of rituximab in the treatment of SS warrants further investigation.

  • RF, rheumatoid factor
  • SS, Sjögren’s syndrome
  • MALT lymphoma
  • Sjögren’s syndrome
  • rituximab
  • treatment

https://doi.org/10.1136/ard.2004.030684

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes